CTLA4 and melanoma: Rationale: Potentiates IFN-I signaling via STAT1/IFNAR1; Preclinical: Enhances anti-CTLA-4 in B16 melanoma. Challenge: ≥250 mg/kg induces liver/kidney toxicity; fails to improve abscopal effect in MC38 models; no human data.